Please Note: This trial is no longer enrolling new participants
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with MTAP Loss and RAS Mutation
| Protocol No. | CTO-TNG462-C102 | Scope | National |
|---|---|---|---|
| Principal Investigator | Anita Turk | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase I/II |
